Table III.
Complete resolution of psoriasis through 52 weeks of treatment by body region
| Week 12 |
|
|
Week 52 |
Week 52 |
|
|---|---|---|---|---|---|
| PBO n = 74 | IXE Q2W n = 75 | p-value | PBO/IXE Q4W n = 65 | IXEa n = 75 | |
| Scalp | 8/62 (12.9) | 51/62 (82.3) | <0.001 | 43/54 (79.6) | 48/61 (78.7) |
| Nail | 5/48 (10.4) | 29/43 (67.4) | <0.001 | 36/42 (85.7) | 36/43 (83.7) |
| Face | 10/38 (26.3) | 37/41 (90.2) | <0.001 | 31/34 (91.2) | 35/41 (85.4) |
| Axilla | 12/29 (41.4) | 17/19 (89.5) | <0.001 | 20/24 (83.3) | 16/19 (84.2) |
| Inframammary fold | 6/24 (25.0) | 20/22 (90.9) | <0.001 | 15/19 (78.9) | 21/22 (95.5) |
| Inguinal creases | 9/46 (19.6) | 34/50 (68.0) | <0.001 | 29/39 (74.4) | 41/50 (82.0) |
| Gluteal cleft | 7/58 (12.1) | 44/55 (80.0) | <0.001 | 39/52 (75.0) | 44/55 (80.0) |
| Perianal | 11/52 (21.2) | 39/48 (81.3) | <0.001 | 37/47 (78.7) | 38/48 (79.2) |
| Pubis | 9/47 (19.1) | 33/39 (84.6) | <0.001 | 33/40 (82.5) | 31/39 (79.5) |
Values are presented as n/N (%) of patients achieving resolution (absence) of psoriasis affecting the indicated body regions (among patients with presence at baseline).
a
Includes all patients initially randomized to IXE Q2W at Week 0.
IXE: ixekizumab; PBO: placebo; Q2W: every 2 weeks; Q4W = every 4 weeks.